Product profile

Real time monitoring of tumor burden： it can be detected with the circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) to evaluate the efficacy of surgical treatment, the efficacy of drug therapy, and the risk of tumor metastasis and recurrence in peripheral blood of patients.

his study selected 52 cases of patients with metastatic breast cancer, molecular markers by monitoring related, such as circulating tumor cells, circulating tumor DNA, CA15-3 to obtain the tumor to treatment response situation.

CtDNA (sensitivity 97%) was detected in the plasma of the 29 patients by using the digital PCR technique in the presence of tumor cells in the presence of mutations in 30 patients. The sensitivity of CTC and CA15-3 were 87% and 78% respectively.

CtDNA is used for tumor load detection, which has a wider range of use and higher tumor burden compared to CTC and CA15-3

CtDNA has higher sensitivity and specificity in real-time monitoring of metastatic breast cancer.